Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$13.65+0.03 (+0.22%)

Close on Nov 13, 2026Market cap $1.94BP/E –Yield –

Trevi Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Trevi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?